Gabapentin Capsule
Product Images NDC 50090-1072

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 50090-1072). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Equation Of Cockcroft And Gault (Gabapentin Fig1)

Equation Of Cockcroft And Gault (Gabapentin Fig1)
This text appears to be a formula or equation used in a medical or scientific context. It seems to be calculating something based on the individual's age and weight. The variable Lt is also mentioned, but its purpose is unclear without further information. The mention of creatinine suggests that this equation may be related to renal function or kidney health. However, due to the errors and lack of context, it is difficult to provide a more specific description.*
FDA Label Image

Figure 1. Weekly Mean Pain Scores (observed Cases In Itt Population): Study 1 (Gabapentin Fig2)

Figure 1. Weekly Mean Pain Scores (observed Cases In Itt Population): Study 1 (Gabapentin Fig2)
FDA Label Image

Figure 2. Weekly Mean Pain Scores (observed Cases In Itt Population): Study 2 (Gabapentin Fig3)

Figure 2. Weekly Mean Pain Scores (observed Cases In Itt Population): Study 2 (Gabapentin Fig3)
FDA Label Image

Figure 3. Proportion Of Responders (patients With ≥50% Reduction In Pain Score) At Endpoint: Controlled Phn Studies (Gabapentin Fig4)

Figure 3. Proportion Of Responders (patients With ≥50% Reduction In Pain Score) At Endpoint: Controlled Phn Studies (Gabapentin Fig4)
Figure 3 shows the proportion of responders in controlled studies on Postherpetic Neuralgia (PHN). The responders are patients who experienced a reduction in pain score of more than 50%. The y-axis represents the percentage of responders, ranging from 0% to 100%. The x-axis displays the different studies (Study 1 and Study 2). The graph indicates that Study 1 had a response rate of approximately 32%, while Study 2 had a response rate of roughly 29%. There are additional data points for different treatment groups (PBO, GBP 3600, GBP 1800, and GBP 2400) represented by bars with different heights. However, the exact values for these treatment groups are not readable.*
FDA Label Image

Figure 4. Responder Rate In Patients Receiving Gabapentin Expressed As A Difference From Placebo By Dose And Study: Adjunctive Therapy Studies In Patients ≥12 Years Of Age With Partial Seizures (Gabapentin Fig5)

Figure 4. Responder Rate In Patients Receiving Gabapentin Expressed As A Difference From Placebo By Dose And Study: Adjunctive Therapy Studies In Patients ≥12 Years Of Age With Partial Seizures (Gabapentin Fig5)
FDA Label Image

Chemical Structure (Gabapentin Str)

Chemical Structure (Gabapentin Str)
FDA Label Image

Label Image (Lbl500901072)

Label Image (Lbl500901072)
This is a description for a product labeled "050-107". The product contains 90 capsules of Gabapentin, with a dosage strength of 480 mg. The Lot Number is indicated as "5981-0".*
FDA Label Image

Label Image (Lbl500901597)

Label Image (Lbl500901597)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.